Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 15,900 shares, an increase of 7.4% from the September 15th total of 14,800 shares. Based on an average daily trading volume, of 5,500 shares, the short-interest ratio is currently 2.9 days. Currently, 0.8% of the shares of the stock are sold short.
Daxor Stock Performance
Shares of NASDAQ:DXR remained flat at $9.00 during trading hours on Wednesday. 284 shares of the stock traded hands, compared to its average volume of 3,931. The company’s 50 day simple moving average is $8.91 and its two-hundred day simple moving average is $9.11. Daxor has a one year low of $7.11 and a one year high of $10.04.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets boosted their price objective on shares of Daxor from $24.50 to $24.75 and gave the stock a “buy” rating in a research note on Monday, September 9th.
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Read More
- Five stocks we like better than Daxor
- What does consumer price index measure?
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is a Bond Market Holiday? How to Invest and Trade
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is the Dow Jones Industrial Average (DJIA)?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
